Gossamer Bio announces 1-for-80 reverse stock split, authorized shares cut to 50M

Chardan initiated coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and $160 price target, citing potential FDA approval of seralutinib for PAH therapy. The stock is near its 52-week low at $9.28. The company has a market cap of $56.76M and faces an NDA decision in Q4 2026. Chardan estimates $1.3B in 2035 revenue if approved. Gossamer recently submitted an NDA for seralutinib, supported by clinical trial data. Leerink and H.C. Wainwright also issued positive ratings.

Gossamer Bio (GOSS) filed an NDA for seralutinib, its treatment for pulmonary arterial hypertension. The submission is based on clinical data from the PROSERA and TORREY studies, though the PROSERA trial did not meet its primary endpoint. GOSS trades at a P/S ratio of 0.62, below its historical median and industry averages, reflecting market skepticism. The company has a GF Score of 22/100, indicating significant financial and operational challenges.

Gossamer Bio submitted an NDA to the FDA for seralutinib to treat pulmonary arterial hypertension. The submission is based on phase 3 PROSERA and phase 2 TORREY study data. The phase 3 trial did not meet its primary endpoint. This is Gossamer's first NDA submission.

Gossamer Bio (GOSS) shares rose 3.7% after-hours after submitting a New Drug Application for seralutinib, a treatment for pulmonary arterial hypertension, to the FDA. The submission is backed by Phase 3 and Phase 2 study data. The FDA will decide whether to accept the application for review later this year.

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

Gossamer Bio (GOSS) filed a Form D notice with the SEC, raising $125M through private securities offerings. The biotech firm, based in San Diego, did not disclose revenue. The offering includes options, warrants, and other rights to acquire securities. Leerink Partners LLC is involved as a broker-dealer.